News | February 19, 2025
Merck’s Welireg receives European approval for two indications
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The drug will target specific genetic mutations prevalent in certain types of cancers
It is the first autotaxin inhibitor to be investigated in cancer patients
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Fluorouracil Injection is indicated for the treatment of patients with adenocarcinoma of colon and rectum and breast
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Subscribe To Our Newsletter & Stay Updated
